NanoViricides is trading 5.2% up at $1.74 today, extending a strong multi-day rally that began earlier in July while moving independently of a broader decline in the biotech sector.
- The stock's advance comes despite a lack of fresh company-specific headlines or analyst actions today.
- Recent corporate filings have highlighted extended executive contracts and an amended credit line, alongside prior updates on the NV-CoV-2 clinical program.